William Blair Has Strong Forecast for NuCana FY2024 Earnings

NuCana plc (NASDAQ:NCNA) – Investment analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of NuCana in a research note issued on Monday, November 25th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($12.76) for the year, up from their previous forecast of ($15.75). William Blair has a “Market Perform” rating on the stock. The consensus estimate for NuCana’s current full-year earnings is ($13.20) per share. William Blair also issued estimates for NuCana’s Q4 2024 earnings at ($2.23) EPS, Q1 2025 earnings at ($2.23) EPS, Q2 2025 earnings at ($2.23) EPS, Q3 2025 earnings at ($2.23) EPS, Q4 2025 earnings at ($2.23) EPS, FY2025 earnings at ($9.57) EPS and FY2026 earnings at ($28.70) EPS.

Separately, Oppenheimer decreased their price target on shares of NuCana from $150.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 3rd.

NuCana Stock Performance

NASDAQ NCNA opened at $1.29 on Thursday. The stock has a 50 day moving average price of $1.90 and a 200-day moving average price of $3.09. NuCana has a one year low of $1.23 and a one year high of $19.41. The company has a market capitalization of $3.41 million, a P/E ratio of -0.11 and a beta of 1.03.

Institutional Investors Weigh In On NuCana

An institutional investor recently bought a new position in NuCana stock. Glass Jacobson Investment Advisors llc bought a new position in NuCana plc (NASDAQ:NCNA) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned 0.57% of NuCana as of its most recent filing with the SEC. Institutional investors own 44.00% of the company’s stock.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.